[go: up one dir, main page]

MX2010002585A - Derivados de piperidina como antagonistas del receptor nk3. - Google Patents

Derivados de piperidina como antagonistas del receptor nk3.

Info

Publication number
MX2010002585A
MX2010002585A MX2010002585A MX2010002585A MX2010002585A MX 2010002585 A MX2010002585 A MX 2010002585A MX 2010002585 A MX2010002585 A MX 2010002585A MX 2010002585 A MX2010002585 A MX 2010002585A MX 2010002585 A MX2010002585 A MX 2010002585A
Authority
MX
Mexico
Prior art keywords
lower alkyl
sub
halogen
substituted
hydrogen
Prior art date
Application number
MX2010002585A
Other languages
English (en)
Inventor
Hasane Ratni
Henner Knust
Matthias Nettekoven
Xihan Wu
Walter Vifian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010002585A publication Critical patent/MX2010002585A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se relaciona con un compuesto de fórmula general (I) en donde Ar1/Ar2 son independientemente uno de otro fenilo o piridinilo, los cuales son opcionalmente sustituidos por uno o dos sustituyentes, seleccionados del grupo que consiste de halógeno, alquilo inferior, alcoxi inferior, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno, alquilo inferior sustituido por alcoxi, alquilo inferior sustituido por ciano, di-alquil amino inferior, piridinilo o ciano; R1 es hidrógeno, alquilo inferior, (CH2)2O-alquil inferior, o cicloalquilo: R2 es -S(O)2-alquil inferior o -C(O)-alquil inferior; o R1 y R2 forman junto con el N-átomo al cual son unidos, un grupo pirrolidin-2-ona o un piperidin-2-ona; R3 es hidrógeno, halógeno o alquilo inferior; R4 es hidrógeno o alquilo inferior; R5/R5'son independientemente uno de otro hidrógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alquilo inferior sustituido por hidroxi o cicloalquilo; o R5 y R5' forman junto con el átomo de carbono al cual son acoplados un grupo cicloalquilo, o a una sal farmacéuticamente activa del mismo. Se ha descubierto que los presentes compuestos son antagonistas de receptor NK-3 de alto potencial para el tratamiento de depresión, dolor, psicosis, enfermedad de Parkinson, esquizofrenia, ansiedad y trastorno de hiperactividad de déficit de atención (ADHD).
MX2010002585A 2007-09-14 2008-09-04 Derivados de piperidina como antagonistas del receptor nk3. MX2010002585A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07116441 2007-09-14
PCT/EP2008/061649 WO2009033995A1 (en) 2007-09-14 2008-09-04 Piperidine derivatives as nk3 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2010002585A true MX2010002585A (es) 2010-03-26

Family

ID=40101126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002585A MX2010002585A (es) 2007-09-14 2008-09-04 Derivados de piperidina como antagonistas del receptor nk3.

Country Status (12)

Country Link
US (2) US20090076081A1 (es)
EP (1) EP2200982B1 (es)
JP (1) JP2010539126A (es)
KR (1) KR101174980B1 (es)
CN (1) CN101801927A (es)
AT (1) ATE549316T1 (es)
AU (1) AU2008297251A1 (es)
BR (1) BRPI0816971A2 (es)
CA (1) CA2699464A1 (es)
ES (1) ES2382415T3 (es)
MX (1) MX2010002585A (es)
WO (1) WO2009033995A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101699738B1 (ko) 2010-04-30 2017-02-13 엘지전자 주식회사 영상표시장치 및 그 셔터 글래스의 동작 제어방법
WO2016158862A1 (ja) * 2015-04-01 2016-10-06 東レ株式会社 整流素子、その製造方法および無線通信装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (es) * 1977-06-03 1981-03-07 Pfizer
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
US5434158A (en) 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
JPH08337569A (ja) * 1995-06-15 1996-12-24 Sankyo Co Ltd 鎮痛活性物質
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
WO2007088181A1 (en) * 2006-02-01 2007-08-09 Solvay Pharmaceuticals Gmbh Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations

Also Published As

Publication number Publication date
US20090076081A1 (en) 2009-03-19
US20110021565A1 (en) 2011-01-27
BRPI0816971A2 (pt) 2015-03-24
EP2200982B1 (en) 2012-03-14
CA2699464A1 (en) 2009-03-19
WO2009033995A1 (en) 2009-03-19
CN101801927A (zh) 2010-08-11
ATE549316T1 (de) 2012-03-15
ES2382415T3 (es) 2012-06-08
EP2200982A1 (en) 2010-06-30
JP2010539126A (ja) 2010-12-16
KR20100040975A (ko) 2010-04-21
KR101174980B1 (ko) 2012-08-17
AU2008297251A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
JO2871B1 (en) Perol compounds
MX2009013115A (es) Derivados de prolinamida como antagonistas de nk3.
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
MX2010001080A (es) Pirrolidin-aril-eteres como antagonistas de receptor de nk3.
HRP20140687T1 (hr) Derivati benzofurana
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
MX2009009384A (es) Malonamidas como antagonistas de orexina.
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
IL201013A0 (en) Quinolines and their therapeutic use
MX2012008147A (es) Derivados de pirrazolopiridina.
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
MX2009010727A (es) Heterociclos como antagonistas de orexina.
MX2012001799A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).
PE20141168A1 (es) Derivados de pirazolidin-3-ona
DE602005007064D1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
MX2010002585A (es) Derivados de piperidina como antagonistas del receptor nk3.
MX2013007411A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2011008178A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2011007506A (es) Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2009006972A (es) Derivados de espiropiperidina como antagonistas de neuroquinina 3.
MX2009013116A (es) Derivados de prolinamida-tetrazol como antagonistas del receptor nk3.

Legal Events

Date Code Title Description
FG Grant or registration